AUTOTELIC BIO
Autotelic Bio is a bio technology company that researches and develops anti-cancer drugs.
AUTOTELIC BIO
Social Links:
Industry:
Biotechnology Pharmaceutical Product Research
Founded:
2015-11-01
Address:
Cheongju, Ch'ungch'ong-bukto, South Korea
Country:
South Korea
Website Url:
http://www.autotelic.co.kr
Total Employee:
11+
Status:
Active
Contact:
+82 43 233 9373
Email Addresses:
[email protected]
Total Funding:
22 B KRW
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF Content Delivery Network JsDelivr Nginx Apache Common Name Invalid PHP Sectigo SSL
Similar Organizations
AL Biotech
AL Biotech is a biotechnology company that develops biopharmaceutical drugs.
Ascol Bio Research Institute
Ascol Bio Research Institute is a biotech company that conducts R&D, product planning, and manufacturing of vitamin C derivatives.
Astrogen
Astrogen is a biotech company developing new drugs.
BeyondBio
BeyondBio is a biotechnology firm that specializes in the research and development of synthetic pharmaceutical drugs.
Genovate Biotechnology Co. Ltd.
Genovate Biotechnology Co. Ltd. is a biotechnology company that provides research and data.
Nosopharm
Nosopharm is a biotechnology company engaged in the research and development of anti-infective drugs.
STC Biologics
STC Biologics is a biotechnology company that offers biologics drug research and development services.
Ticaros
Ticaros is a biotech company that develops immune anti-cancer drugs.
YZY Bio
YZY Bio is a biotechnology company that develops anti-tumor bispecific antibodies.
Investors List
LSK Investment
LSK Investment investment in Series B - Autotelic Bio
Stonebridge Capital
Stonebridge Capital investment in Series B - Autotelic Bio
Sejong Venture Partners
Sejong Venture Partners investment in Series B - Autotelic Bio
Woori Bank
Woori Bank investment in Series B - Autotelic Bio
UTC Investment Co.
UTC Investment Co. investment in Series B - Autotelic Bio
DT Investments
DT Investments investment in Series B - Autotelic Bio
JB Ventures
JB Ventures investment in Series B - Autotelic Bio
ST Pharm
ST Pharm investment in Series A - Autotelic Bio
Jeil Pharmaceutical
Jeil Pharmaceutical investment in Series A - Autotelic Bio
UTC Investment Co.
UTC Investment Co. investment in Series A - Autotelic Bio
Official Site Inspections
http://www.autotelic.co.kr Semrush global rank: 5.58 M Semrush visits lastest month: 1.29 K
- Host name: 58.230.162.176
- IP address: 58.230.162.176
- Location: Daegu South Korea
- Latitude: 35.8723
- Longitude: 128.5924
- Timezone: Asia/Seoul
- Postal: 41934
More informations about "Autotelic Bio"
์คํ ํ ๋ฆญ๋ฐ์ด์ค AutotelicBio
Global Leader of Cancer Treatment. Innovative new drugs available to cancer patients. ASO new drugs are presented by innovative oligonucleotide designs through informatics technology โฆSee details»
์คํ ํ ๋ฆญ๋ฐ์ด์ค AutotelicBio
Global Leader of Cancer Treatment. Innovative new drugs available to cancer patients. Anti-Sense Oligonucleotide (ASO) ์ ์ฝ์ informatics technology ASODE+ ๋ฐ CATs platform์ โฆSee details»
Leadership - ์คํ ํ ๋ฆญ๋ฐ์ด์ค AutotelicBio
Experience. Boryung Pharm, New Drug Global Business Team Head (Kanarb®) Huya Bioscience, Licensing part, San Diego, CA., USA; Boryung Pharm, KT&G Life Science, and โฆSee details»
Autotelic Bio - Crunchbase Company Profile & Funding
Autotelic Bio is a bio technology company that researches and develops anti-cancer drugs. ... Solutions. Products. Resources. Pricing. Resources. Log In. Organization. Autotelic Bio . โฆSee details»
Autotelic Bio Raised Strategic Investment - News - ์คํ ํ ๋ฆญ๋ฐ์ด์ค โฆ
Autotelic Bio, an ASO (Anti-sense Oligonucleotide)-based innovative new drug development company, announced on December 11 that it has raised strategic investment worth of KRW 3 โฆSee details»
Autotelic Bio Successfully Raised KRW 15.5 Billlion in Series B ...
Autotelic Bio, an RNA based ASO (Anti-sense Oligonucleotide) innovative new drug development company, announced that it has successfully completed a Series B round investment, raising โฆSee details»
์คํ ํ ๋ฆญ๋ฐ์ด์ค AutotelicBio
2019. Dec. Series A Round with Mega Investment & UTC Investment Nov. Immuno-oncology R&D Grant (Medical Innovation Foundation) Oct. Investment Agreement with Aju Pharm & โฆSee details»
Autotelic Bio Company Profile 2024: Valuation, Funding
Autotelic Bio General Information Description. Developer of anti-cancer drugs designed to treat cancer patients. The company focuses on developing anti-cancer drugs for selective targeting โฆSee details»
์คํ ํ ๋ฆญ๋ฐ์ด์ค AutotelicBio
Vision Global Leader of Cancer Treatments. Autotelic Bio aims to develop undruggable-target anti-cancer drugs to improve the effectiveness and reduce the side effects of existing cancer โฆSee details»
์คํ ํ ๋ฆญ๋ฐ์ด์ค AutotelicBio
Autotelic Bio and Chinoin Announce Exclusive License and Supply Agreement for ATB-101 in Mexico. 2024-06-07See details»
์คํ ํ ๋ฆญ๋ฐ์ด์ค AutotelicBio
E-mail: [email protected] Phone number: 070-4123-5311. You can report any personal information protection-related complaints arising from use of the company's services to the โฆSee details»
์คํ ํ ๋ฆญ๋ฐ์ด์ค AutotelicBio
Autotelic Bio, Dream CIS and Tigermed Signed an MOU for Mutual Cooperation for Global New Drug Development and Strategic Investment ... April 2023 ๏ธ. 2023-04-28. Press Release. โฆSee details»
์คํ ํ ๋ฆญ๋ฐ์ด์ค AutotelicBio
CATsโข (Conjugated ASO Targeting Solution) is Autotelic Bio's platform technology, which enables the derivation of novel molecules by utilizing conjugate techniques between โฆSee details»
ASODEโข Platform - autotelic.co.kr
ASODEโข Platform. ASODEโข (Anti-Sense Oligonucleotide Development) is Autotelic Bioโs ASO new drug development system which includes the whole processes of ASO sequence design, โฆSee details»
Pipeline - ์คํ ํ ๋ฆญ๋ฐ์ด์ค AutotelicBio
Privacy Policy; Headquarter. #302, 194-41, Osong-saengmyeong 1-ro, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, 28610, Republic of Korea R&D Center. #510 ...See details»
News - autotelic.co.kr
Taehun Kim, CEO of Autotelic Bio, said, โ The IPF field is a market with high unmet medical needs due to the limitation of existing treatments and the market is expected to grow to more โฆSee details»
ASO (Anti-sense Oligonucleotide) - autotelic.co.kr
02. Science & Innovation Features. 18-mer phosphorothioate Anti-sense Oligonucleotide targeting human TGF-ฮฒ2; Designed based on the correlation between TGF-ฮฒ overexpression and tumor โฆSee details»
News - ์คํ ํ ๋ฆญ๋ฐ์ด์ค AutotelicBio
Jeil Pharmaceutical has signed a Joint Development and Technology Transfer Agreement with Autotelic Bio for the collaborative development of ATB-101, a fixed dose combination new โฆSee details»
์คํ ํ ๋ฆญ๋ฐ์ด์ค AutotelicBio
Autotelic Bio to Initiate Phase 3 Clinical Trial for ATB-101, the World's 1st FDC for Hypertension and Diabetes. 2022-07-04See details»
Autotelic Bio to Initiate Phase 3 Clinical Trial for ATB-101, the โฆ
Autotelic Bio's ATB-101 is an IMD (incrementally modified drug) of olmesartan, an anti-hypertension agent, and dapagliflozin, an oral diabetes treatment, and is a combination drug โฆSee details»